Premium
Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib
Author(s) -
Kim Gene H.,
Levy Alan,
Compoginis Goli
Publication year - 2013
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.12149
Subject(s) - vemurafenib , medicine , metastatic melanoma , panniculitis , melanoma , v600e , dermatology , pathology , nodular melanoma , oncology , cancer research , mutation , biochemistry , chemistry , gene
Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation. Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor. We present an additional case and review the clinical findings of the cases reported to date.